There are so many examples of how better understanding of the natural history of diseases helps improve people’s care.
In the case of the presymptomatic stages of type 1 diabetes, identifying markers of disease progression will be pivotal for choosing the right monitoring cadence and management for each person. That’s why here at European Association for the Study of Diabetes e.V. (EASD), investigators are making our heads spin showing us they are on a fast track to find factors of prediction of disease progression.
Just a few examples:
- Teams at the Helmholtz Munich are improving polygenic risk scores and enhancing the precision of metabolic staging.
- On the other side of the Atlantic, Prof. Emily Sims collected compelling evidence that positivity for IA-2A is associated with a high risk of progression independently from glycemic status.
Like I said, the more people at high risk of fast progression can be identified, the better the care and the softer the transition to stage 3 T1D.
Want to know more about Islet autoantibodies as precision diagnostic tools in aT1D? Felton JL et al, Commun Med (Lond). 2024 Apr 6;4(1):66. doi: 10.1038/s43856-024-00478-y. PMID: 38582818; PMCID: PMC10998887.Islet autoantibodies as precision diagnostic tools to characterize heterogeneity in type 1 diabetes: a systematic review - PMC (nih.gov)
#naturalhistory, #type1diabetes, #precisionmedicine, #earlydetection
CEO at Cellexus International Ltd
2moCongratulations